Cantargia AB (SE:CANTA)
:CANTA
Top Page
Cantargia AB
(CANTA)
Select Model
Select Model
Rating:55Neutral
Price Target:
kr4.00
▼(-0.99% Downside)
Action:ReiteratedDate:02/21/26
The score is driven by improved 2025 financial performance (profitability and strong cash generation) but tempered by limited multi-year consistency and historically heavy losses typical of biotech. Technicals are a notable drag with the stock trading below key short-term moving averages and weak momentum, while valuation (P/E ~10) provides partial support.
Positive Factors
Debt-free balance sheet
The company reports zero debt across all periods, which materially reduces financial risk and interest burden. This strengthens long-term flexibility to fund R&D, weather biotech development cycles, and negotiate partnerships without near-term refinancing pressure.
Negative Factors
Historic multi-year losses and equity decline
Several years of losses and cash burn reduced the company’s equity base, weakening balance sheet durability prior to 2025. This history implies limited track record of sustained profitability and increases sensitivity to future setbacks or the need for external capital to maintain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The company reports zero debt across all periods, which materially reduces financial risk and interest burden. This strengthens long-term flexibility to fund R&D, weather biotech development cycles, and negotiate partnerships without near-term refinancing pressure.
Read all positive factors
Cantargia AB (CANTA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr982.02M
Dividend YieldN/A
Average Volume (3M)1.42M
Price to Earnings (P/E)7.1
Beta (1Y)0.79
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr14.00Price Target Upside246.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.63
Revenue Forecast (FY)kr2.93M
Cantargia AB Business Overview & Revenue Model
Company Description
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP...
How the Company Makes Money
Cantargia primarily makes money through (1) collaboration and licensing income tied to its drug-development programs and platform, and (2) potentially, future product revenue if any candidates reach commercialization (none confirmed as marketed pr...
Cantargia AB Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 316.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 316.70M | -3.44M | -3.45M | -3.69M | -3.45M |
| EBITDA | 157.66M | -165.05M | -284.31M | -368.12M | -363.06M |
| Net Income | 146.97M | -161.65M | -280.03M | -371.81M | -366.50M |
Balance Sheet | |||||
| Total Assets | 296.66M | 170.43M | 223.71M | 474.80M | 600.24M |
| Cash, Cash Equivalents and Short-Term Investments | 281.82M | 33.04M | 194.75M | 426.67M | 559.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 30.78M | 54.12M | 54.97M | 85.11M | 67.50M |
| Stockholders Equity | 265.88M | 116.30M | 168.74M | 389.68M | 532.75M |
Cash Flow | |||||
| Free Cash Flow | 149.66M | -162.75M | -286.66M | -366.00M | -346.83M |
| Operating Cash Flow | 150.13M | -162.75M | -286.66M | -358.92M | -346.44M |
| Investing Cash Flow | -472.00K | 55.00M | 182.09M | 67.88M | -102.43M |
| Financing Cash Flow | 103.86M | -1.07M | 54.68M | 223.93M | 3.00K |
Cantargia AB Technical Analysis
Negative
4.04
Price Trends
4.86
Negative
4.37
Negative
3.39
Positive
Market Momentum
-0.24
Negative
39.70
Neutral
31.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CANTA, the sentiment is Negative. The current price of 4.04 is below the 20-day moving average (MA) of 4.15, below the 50-day MA of 4.86, and above the 200-day MA of 3.39, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 31.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CANTA.
Cantargia AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:CANTA
Cantargia AB
3.95
2.48
167.80%
SE:ONCO
Oncopeptides AB
1.51
0.17
12.30%
DE:8F8
SynAct Pharma AB
1.57
0.13
9.15%
DE:5LH0
Guard Therapeutics International AB
0.04
-1.27
-96.72%
DE:1YG0
Immunicum AB
0.37
-0.23
-38.73%
Cantargia AB Corporate Events
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
Mar 18, 2026
Cantargia has reported new preclinical data showing that a murine surrogate of its anti-IL1RAP antibody nadunolimab can reduce immunosuppression in metastatic colorectal cancer, particularly when combined with an anti-PD-1 immune-checkpoint inhibi...
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
Mar 5, 2026
Cantargia AB will engage in one-on-one investor and partner meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 16, 2026, as part of its outreach to the life sciences investment community. Participation in this speci...
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
Feb 23, 2026
Cantargia AB will participate in TD Cowen’s 46th Annual Health Care Conference in Boston from March 2 to 4, 2026, where members of its management team will also host one‑on‑one meetings with investors and other stakeholders. The ...
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
Feb 20, 2026
Cantargia’s year-end report for January to December 2025 outlines progress across its pipeline of antibody-based drug candidates targeting cancer and severe immunological diseases. The report highlights the company’s continued developm...
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
Feb 6, 2026
Cantargia will publish its annual results for 2025 on 20 February 2026 and will host an English-language audiocast and teleconference later that day, where CEO Hilde Steineger and CFO Patrik Renblad will present the results and take questions from...
Cantargia to Engage Investors at Leerink Global Healthcare Conference
Jan 28, 2026
Cantargia announced that its management team will hold one-on-one meetings with investors and stakeholders at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. Participation in this high-profile sector event underscores...
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
Jan 23, 2026
Cantargia AB has announced that the first patient has been dosed in a Phase 1b/2 investigator-initiated trial at the Tisch Cancer Institute, Mount Sinai, testing its IL1RAP-targeting antibody nadunolimab in combination with an anti-PD-1 checkpoint...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.